Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

While 72 million Americans have back pain often attributed to mechanical issues, an estimated 5 million are actually living with inflammatory back pain caused by an autoimmune condition. This reframes a significant portion of chronic back pain from a common mechanical problem to a major, undiagnosed immunological disease hidden in plain sight.

T-cells have natural inhibitory signals, or "brakes" (like PD-1), to prevent over-activation. Some cancers exploit this. Checkpoint inhibitor drugs block these brakes, unleashing a patient's existing T-cells to attack cancer cells more aggressively. This approach has been miraculous for cancers like melanoma.

The thymus is where randomly generated T-cells are tested. Through a process called negative selection, any T-cell whose receptor engages with a "self-target" is programmed to die. This ensures that the T-cells emerging from the thymus are primed to attack foreign invaders, not the body itself.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

Dr. Holman argues the autonomic nervous system is an overlooked therapeutic target with vast potential. By modulating this system, innovators can address root causes of not just autoimmune disorders but also cancer, cardiovascular disease, and diabetes. He calls this emerging field "immunoautonomics."

Dr. Will Bolsiewicz distinguishes between life-saving acute inflammation (fighting infection, healing injury) and detrimental chronic low-grade inflammation. The latter is a constant, damaging immune response likened to a “forever war” inside the body, which is at the root of many modern diseases.

The immune system deploys powerful "weapons" to fight invaders. However, an over-activated response, triggered by proteins like C5a, can cause these weapons to harm the body's own organs and tissues, similar to the collateral damage from a dirty bomb.